Hallek lab

Translational CLL research to develop new standards of clinical care

Our research is focused on identifying new pathways with relevance for the pathogenesis of CLL. To pursue this aim, we employ in vitro biochemical assays, as well as genetically engineered mouse models. We further aim to develop novel, targeted therapies for CLL patients with the aim to achieve a non-toxic, long-term control of this leukemia entity. For that purpose, we perform early phase clinical trials, as well as large approval trials within the German CLL Study Group.

Prof. Dr. Michael Hallek

Department I of Internal Medicine
Center of Integrated Oncology ABCD
University Hospital of Cologne
Kerpener Str. 62
50937 Cologne

Tel. +49 221 478-39706

Find out more:

CIO Cologne
Deutsche CLL Studiengruppe
Department I of Internal Medicine
Michael Hallek@CECAD Cologne